Opticyte, Inc, a medical device innovator developing proprietary advanced algorithms and tailored optical spectroscopy technology to measure and detect low oxygen levels in cells to prevent organ failure. Opticyte is developing the first Cell O2 Monitor for reducing organ failure.
One of the primary goals of clinicians caring for critically ill patients is to restore and maintain sufficient oxygen levels in the body’s tissues and organs. Prolonged periods of low tissue and organ oxygen levels lead to clinical shock, resulting in multiple organ failure, loss of limbs, and death. Current measurement methods are too slow or rely on indirect clinical information, leaving clinicians guessing at patient condition, treatment protocol, and treatment effectiveness. Clinicians need a device that provides direct monitoring of cellular oxygenation to provide real-time information on patient condition and treatment effectiveness.
Total Funding: $5.7 M
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2016
